This week’s Medical Minute, discusses “Remote Ischemic Conditioning”, a relatively simple technique that scientist hope will become a useful treatment for Hemorrhagic strokes, the most deadly type of stroke.
Researchers found that a class of antibodies in a monkey's blood provides protection from COVID-19. If that hold true for humans, a blood test may predict whether a vaccine candidate is working.
The Pfizer-BioNTech COVID-19 vaccine was developed fast. But a leading vaccine expert says its important for consumers to know the companies "haven't cut corners" in the clinical science.
The U.S. government says it will issue a vaccine card and use other tools to help millions of Americans follow through with their immunizations against COVID-19.
The biotech company has new data reinforcing that its COVID-19 inoculation is safe and effective. Moderna is submitting an application to the FDA requesting emergency use authorization.
The medicines from Eli Lilly and Regeneron are infused, a process that can take two hours or longer, including observation for side effects. Staffing is as big an issue as the supply of the drugs.
The $1.95 billion Operation Warp Speed contract excludes government rights to inventions or production know-how developed in the manufacture of the COVID-19 vaccine.
Operation Warp Speed is allocating the first batch of 6.4 million COVID vaccines to states, based on population. This circumvents a CDC advisory committee, which proposed allocation based on risk.
A newly approved drug can extend the lives of children with progeria, a rare disorder that causes rapid aging. The drug is the result of one family's effort to help a child with the fatal condition.
When Kansas issued a mask mandate, 81 counties opted out. Researchers found coronavirus infection rates rose sharply in the opt-out counties, while falling in those that required masks.
Watch an expert panel discussion on the effort to develop and deploy safe and effective vaccines against COVID-19 on Friday, Nov. 20, to be live-streamed here at 12 p.m. ET
The pharmaceutical giant and partner BioNTech announced Friday that they are submitting a formal request to the Food and Drug Administration, just days after the vaccine was shown to be 95% effective.
Albert Bourla, head of the pharmaceutical giant, discusses plans for distributing its vaccine, which it says is 95% effective, and explains the timing of his $5.6 mllion sale of Pfizer stock.